Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success.
Becker
J C
JC
Muller-Tidow
C
C
Serve
H
H
Domschke
W
W
Pohle
T
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000503:physiopathology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D000068258:Bevacizumab; D000068818:Cetuximab; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D018773:Genes, erbB-1 / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D000068258:Bevacizumab; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D020794:Receptor Protein-Tyrosine Kinases; D000068878:Trastuzumab; D000068818:Cetuximab; D000077156:Gefitinib